Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ravandi, Farhad"'
Autor:
Ravandi, Farhad, O'Brien, Susan M, Cortes, Jorge E, Thomas, Deborah M, Garris, Rebecca, Faderl, Stefan, Burger, Jan A, Rytting, Michael E, Ferrajoli, Alessandra, Wierda, William G, Verstovsek, Srdan, Champlin, Richard, Kebriaei, Partow, McCue, Deborah A, Huang, Xuelin, Jabbour, Elias, Garcia-Manero, Guillermo, Estrov, Zeev, Kantarjian, Hagop M
Publikováno v:
Cancer, vol 121, iss 23
BackgroundThe long-term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is not well established.MethodsPatients received dasatinib with 8 cycles of alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::7278ab2cfee51768d806759d49b4d4ab
https://escholarship.org/uc/item/6c75k8qv
https://escholarship.org/uc/item/6c75k8qv
Autor:
Yilmaz, Musa, Lahoti, Amit, O'Brien, Susan, Nogueras-González, Graciela M, Burger, Jan, Ferrajoli, Alessandra, Borthakur, Gautam, Ravandi, Farhad, Pierce, Sherry, Jabbour, Elias, Kantarjian, Hagop, Cortes, Jorge E
Publikováno v:
Cancer, vol 121, iss 21
BackgroundChronic use of tyrosine kinase inhibitors (TKIs) may lead to previously unrecognized adverse events. This study evaluated the incidence of acute kidney injury (AKI) and chronic kidney disease (CKD) in chronic-phase (CP) chronic myeloid leuk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::a19632f0b9923ba4a8af1a06763902a4
https://escholarship.org/uc/item/7gc7p27s
https://escholarship.org/uc/item/7gc7p27s
Autor:
Badar, Talha, Shetty, Aditya, Bueso-Ramos, Carlos, Cortes, Jorge, Konopleva, Marina, Borthakur, Gautam, Pierce, Sherry, Huang, Xuelin, Chen, Hsiang-Chun, Kadia, Tapan, Daver, Naval, Dinardo, Courtney, O'Brien, Susan, Garcia-Manero, Guillermo, Kantarjian, Hagop, Ravandi, Farhad
Publikováno v:
American journal of hematology, vol 90, iss 9
Bone marrow necrosis (BMN) is characterized by infarction of the medullary stroma, leading to marrow necrosis with preserved cortical bone. In reported small series, BMN in hematological malignancies is associated with poor prognosis. We sought to fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::b7cfcd59d5cb683cf212f284d306f5e3
https://escholarship.org/uc/item/3qm2b58w
https://escholarship.org/uc/item/3qm2b58w
Autor:
Sasaki, Koji, Strom, Sara S, O'Brien, Susan, Jabbour, Elias, Ravandi, Farhad, Konopleva, Marina, Borthakur, Gautam, Pemmaraju, Naveen, Daver, Naval, Jain, Preetesh, Pierce, Sherry, Kantarjian, Hagop, Cortes, Jorge E
Publikováno v:
The Lancet. Haematology, vol 2, iss 5
BackgroundTyrosine-kinase inhibitors improve overall survival in patients with chronic myeloid leukaemia in chronic phase (CML-CP). Survival compared with the general population by age, response, and type of tyrosine-kinase inhibitor is not known. Wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::36339a37a4f94c95972ce12537cb01d4
https://escholarship.org/uc/item/2862n1m9
https://escholarship.org/uc/item/2862n1m9
Autor:
Jain, Preetesh, Kantarjian, Hagop, Alattar, Mona Lisa, Jabbour, Elias, Sasaki, Koji, Nogueras Gonzalez, Graciela, Dellasala, Sara, Pierce, Sherry, Verstovsek, Srdan, Wierda, William, Borthakur, Gautam, Ravandi, Farhad, O'Brien, Susan, Cortes, Jorge
Publikováno v:
The Lancet. Haematology, vol 2, iss 3
BackgroundSeveral tyrosine kinase inhibitors (TKIs) are available for treatment of patients with chronic myeloid leukaemia in chronic phase (CML-CP). We analysed long-term molecular and cytogenetic response and survival outcomes for four TKI modaliti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::3be70573fa96a9ba8931bf507a5ddde1
https://escholarship.org/uc/item/0rx3x497
https://escholarship.org/uc/item/0rx3x497
Autor:
Kadia, Tapan M, Kantarjian, Hagop M, Thomas, Deborah A, O'Brien, Susan, Estrov, Zeev, Ravandi, Farhad, Jabbour, Elias, Pemmaraju, Naveen, Daver, Naval, Wang, Xuemei, Jain, Preetesh, Pierce, Sherry, Brandt, Mark, Garcia-Manero, Guillermo, Cortes, Jorge, Borthakur, Gautam
Publikováno v:
American journal of hematology, vol 90, iss 2
Newer approaches are needed for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). Asparaginase-based regimens are active in the treatment of pediatric ALL and may be important in salvage therapy for adult patients. We condu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::af6fc181aead03006d3f406726594d53
https://escholarship.org/uc/item/0112c32h
https://escholarship.org/uc/item/0112c32h
Autor:
Faderl, Stefan, Balakrishnan, Kumudha, Thomas, Deborah A, Ravandi, Farhad, Borthakur, Gautam, Burger, Jan, Ferrajoli, Alessandra, Cortes, Jorge, O'Brien, Susan, Kadia, Tapan, Feliu, Jennie, Plunkett, William, Gandhi, Varsha, Kantarjian, Hagop M
Publikováno v:
Clinical lymphoma, myeloma & leukemia, vol 14, iss 3
BackgroundClofarabine is a nucleoside analogue with activity in children with acute lymphoblastic leukemia (ALL). Based on the hypothesis that clofarabine inhibits DNA repair after exposure to DNA-damaging agents, we designed a phase I and extension
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::8277d609c4d4050d3aeb5bc4ba565e03
https://escholarship.org/uc/item/3047s33c
https://escholarship.org/uc/item/3047s33c
Autor:
Jabbour, Elias, Ghanem, Hady, Huang, Xuelin, Ravandi, Farhad, Garcia-Manero, Guillermo, O'Brien, Susan, Faderl, Stephan, Pierce, Sherry, Choi, Sangbum, Verstovsek, Srdan, Brandt, Mark, Cortes, Jorge, Kantarjian, Hagop
Publikováno v:
Clinical lymphoma, myeloma & leukemia, vol 14, iss 2
We assessed the outcomes of 63 patients with acute myeloid leukemia (AML) arising from myelodysplastic syndrome (MDS) after hypomethylating agent failure. Their median age was 63 years. All 63 patients had received ≥ 1 salvage regimens for AML, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::58bf2f614cc7b4a044a7ec42d32d9226
https://escholarship.org/uc/item/28t6k2m8
https://escholarship.org/uc/item/28t6k2m8
Autor:
Benjamini, Ohad, Dumlao, Theresa Liu, Kantarjian, Hagop, O'Brien, Susan, Garcia-Manero, Guillermo, Faderl, Stefan, Jorgensen, Jeffrey, Luthra, Rajyalakshmi, Garris, Rebecca, Thomas, Deborah, Kebriaei, Partow, Champlin, Richard, Jabbour, Elias, Burger, Jan, Cortes, Jorge, Ravandi, Farhad
Publikováno v:
American journal of hematology, vol 89, iss 3
Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::8860c7d71e27a80c5be028c0d9366580
https://escholarship.org/uc/item/3rg3f954
https://escholarship.org/uc/item/3rg3f954
Autor:
Strati, Paolo, Kantarjian, Hagop, Thomas, Deborah, O'Brien, Susan, Konoplev, Sergej, Jorgensen, Jeffrey L, Luthra, Raja, Abruzzo, Lynne, Jabbour, Elias, Quintas-Cardama, Alfonso, Borthakur, Gautam, Faderl, Stefan, Ravandi, Farhad, Cortes, Jorge
Publikováno v:
Cancer, vol 120, iss 3
BackgroundChronic myeloid leukemia (CML) may progress to blast phase (BP) at the rate of 1% to 1.5% per year. With the use of single-agent tyrosine kinase inhibitors, median overall survival ranges between 7 and 11 months.MethodsThe outcome was analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::0c11b63ea28733d7b1725c658813a6f2
https://escholarship.org/uc/item/5290654w
https://escholarship.org/uc/item/5290654w